From: Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
6 Monthsa | 12 Monthsa | 18 Monthsa | |
---|---|---|---|
Among INF bio-originator prevalent users | |||
< 12 months prior use of INF bio-originator | 0.94 [0.92–0.97] * | 0.87 [0.83–0.91] * | 0.77 [0.73–0.82] * |
≥ 12 months prior use of INF bio-originator | Reference | Reference | Reference |
Among INF biosimilar prevalent users | |||
< 12 months prior use of INF bio-originator | 0.81 [0.52–1.25] | 0.65 [0.35–1.21] | 0.64 [0.18–2.35] |
≥ 12 months prior use of INF bio-originator | Reference | Reference | Reference |
All prevalent INF users with < 12 months prior | |||
Use of INF bio-originator | |||
INF biosimilar | 0.76 [0.53–1.10] | 0.61 [0.35–1.06] | 0.59 [0.18–1.97] |
INF bio-originator | Reference | Reference | Reference |
All prevalent users with ≥ 12 months prior | |||
Use of INF bio-originator | |||
INF biosimilar | 0.70 [0.62–0.80] * | 0.63 [0.52–0.76] * | 0.56 [0.39–0.80] * |
INF bio-originator | Reference | Reference | Reference |